Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 33.64 CNY, compared to the current stock price of 27.99 CNY as of March 26, 2026 [3]. Core Insights - The company achieved a revenue of 31.603 billion CNY in 2025, representing a year-on-year growth of 14.43%. The net profit attributable to shareholders was 3.421 billion CNY, with a growth of 1.58% year-on-year. The fourth quarter showed a strong recovery with a revenue of 9.616 billion CNY, up 22.09% year-on-year, and a net profit of 1.068 billion CNY, up 161.77% year-on-year [1][2]. - The gross margin for 2025 was 54.03%, an increase of 2.17 percentage points year-on-year. The company maintained good control over overall expense ratios, with a total expense ratio of 38.89%, up 3.93 percentage points year-on-year [1]. - The company has established a robust business structure with the integration of Tian Shi Li, leading to significant growth in the prescription drug segment, which saw a revenue increase of 101.38% year-on-year [2][3]. Financial Performance - In 2025, the CHC business generated a revenue of 15.111 billion CNY, a decline of 14.67% year-on-year, while the prescription drug business generated 12.094 billion CNY, reflecting a substantial increase due to the merger with Tian Shi Li [2]. - The company successfully completed its strategic goal of doubling revenue during the "14th Five-Year Plan" period, increasing the number of products exceeding 100 million CNY from 21 to 45 [3][6]. - Forecasts for revenue growth from 2026 to 2028 are 8.4%, 7.6%, and 7.4%, respectively, with net profit growth of 9.1%, 8.8%, and 8.7% [6][7]. Business Strategy - The company aims to benchmark against world-class enterprises during the "15th Five-Year Plan" period, focusing on product excellence, brand recognition, and innovation in traditional Chinese medicine [6]. - The company has enhanced its R&D investment from 581 million CNY in 2020 to 1.734 billion CNY in 2025, with a total of 38 approved products [6].

Core Viewpoint - China Resources Sanjiu's performance fell short of expectations in the first half of 2025, primarily due to a decrease in the incidence of respiratory diseases and adjustments in retail channels [1] Group 1: Financial Performance - The company's profit decline is significantly attributed to the completion of the Tian Shi Li acquisition, which increased the sales expense ratio due to the focus on hospital sales in Tian Shi Li's traditional Chinese medicine business [1] - The wholesale and retail business for pharmaceuticals and medical devices showed steady growth, achieving revenue of 1.74 billion yuan, a year-on-year increase of 3.3% [1] Group 2: Business Outlook - The pressure on the CHC (Consumer Health Care) business is considered temporary, with the company’s channel and brand advantages continuing to empower its business layout [1] - The company is expanding into cell therapy, metabolism, and oncology sectors [1] Group 3: Valuation - Based on the average price-to-earnings ratio of comparable companies, a valuation of 22 times PE for 2025 is suggested, corresponding to a target price of 45.10 yuan, maintaining a "buy" rating [1]